MONOACYLGLYCEROL LIPASE MODULATORS
3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | GARCIA-REYNAGA, Pablo LAFORTEZA, Brian Ngo AMERIKS, Michael K BERRY, Cynthia B LIANG, Jimmy T |
| description | 3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein X, Y, R1, R2a, and R2b are defined herein.
L'invention concerne des composés azabicycliques 3.1.0 et 4.1.0 de formule (I), des compositions pharmaceutiques les contenant, des procédés de fabrication de ceux-ci, et des procédés d'utilisation de ceux-ci comprenant des procédés de traitement d'états pathologiques, de troubles, et de conditions associées à la modulation de MGL, telles que celles associées à la douleur, à des troubles psychiatriques, à des troubles neurologiques (notamment, entre autres, le trouble dépressif majeur, la dépression résistante aux traitements, la dépression anxieuse, le trouble bipolaire), des cancers et des affections oculaires. Dans la formule, X, Y, R1, R2a et R2b sont tels que définis dans la description. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2021160602A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2021160602A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2021160602A13</originalsourceid><addsrcrecordid>eNrjZFDy9ffzd3SO9HH3iXR2DfL3UfDxDHAMdlXw9XcJ9XEM8Q8K5mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgZGhoZmBmYGRo6GxsSpAgDrqiOs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MONOACYLGLYCEROL LIPASE MODULATORS</title><source>esp@cenet</source><creator>GARCIA-REYNAGA, Pablo ; LAFORTEZA, Brian Ngo ; AMERIKS, Michael K ; BERRY, Cynthia B ; LIANG, Jimmy T</creator><creatorcontrib>GARCIA-REYNAGA, Pablo ; LAFORTEZA, Brian Ngo ; AMERIKS, Michael K ; BERRY, Cynthia B ; LIANG, Jimmy T</creatorcontrib><description>3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein X, Y, R1, R2a, and R2b are defined herein.
L'invention concerne des composés azabicycliques 3.1.0 et 4.1.0 de formule (I), des compositions pharmaceutiques les contenant, des procédés de fabrication de ceux-ci, et des procédés d'utilisation de ceux-ci comprenant des procédés de traitement d'états pathologiques, de troubles, et de conditions associées à la modulation de MGL, telles que celles associées à la douleur, à des troubles psychiatriques, à des troubles neurologiques (notamment, entre autres, le trouble dépressif majeur, la dépression résistante aux traitements, la dépression anxieuse, le trouble bipolaire), des cancers et des affections oculaires. Dans la formule, X, Y, R1, R2a et R2b sont tels que définis dans la description.</description><language>eng ; fre</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2021</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210819&DB=EPODOC&CC=WO&NR=2021160602A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210819&DB=EPODOC&CC=WO&NR=2021160602A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GARCIA-REYNAGA, Pablo</creatorcontrib><creatorcontrib>LAFORTEZA, Brian Ngo</creatorcontrib><creatorcontrib>AMERIKS, Michael K</creatorcontrib><creatorcontrib>BERRY, Cynthia B</creatorcontrib><creatorcontrib>LIANG, Jimmy T</creatorcontrib><title>MONOACYLGLYCEROL LIPASE MODULATORS</title><description>3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein X, Y, R1, R2a, and R2b are defined herein.
L'invention concerne des composés azabicycliques 3.1.0 et 4.1.0 de formule (I), des compositions pharmaceutiques les contenant, des procédés de fabrication de ceux-ci, et des procédés d'utilisation de ceux-ci comprenant des procédés de traitement d'états pathologiques, de troubles, et de conditions associées à la modulation de MGL, telles que celles associées à la douleur, à des troubles psychiatriques, à des troubles neurologiques (notamment, entre autres, le trouble dépressif majeur, la dépression résistante aux traitements, la dépression anxieuse, le trouble bipolaire), des cancers et des affections oculaires. Dans la formule, X, Y, R1, R2a et R2b sont tels que définis dans la description.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2021</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFDy9ffzd3SO9HH3iXR2DfL3UfDxDHAMdlXw9XcJ9XEM8Q8K5mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgZGhoZmBmYGRo6GxsSpAgDrqiOs</recordid><startdate>20210819</startdate><enddate>20210819</enddate><creator>GARCIA-REYNAGA, Pablo</creator><creator>LAFORTEZA, Brian Ngo</creator><creator>AMERIKS, Michael K</creator><creator>BERRY, Cynthia B</creator><creator>LIANG, Jimmy T</creator><scope>EVB</scope></search><sort><creationdate>20210819</creationdate><title>MONOACYLGLYCEROL LIPASE MODULATORS</title><author>GARCIA-REYNAGA, Pablo ; LAFORTEZA, Brian Ngo ; AMERIKS, Michael K ; BERRY, Cynthia B ; LIANG, Jimmy T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2021160602A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2021</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>GARCIA-REYNAGA, Pablo</creatorcontrib><creatorcontrib>LAFORTEZA, Brian Ngo</creatorcontrib><creatorcontrib>AMERIKS, Michael K</creatorcontrib><creatorcontrib>BERRY, Cynthia B</creatorcontrib><creatorcontrib>LIANG, Jimmy T</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GARCIA-REYNAGA, Pablo</au><au>LAFORTEZA, Brian Ngo</au><au>AMERIKS, Michael K</au><au>BERRY, Cynthia B</au><au>LIANG, Jimmy T</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MONOACYLGLYCEROL LIPASE MODULATORS</title><date>2021-08-19</date><risdate>2021</risdate><abstract>3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein X, Y, R1, R2a, and R2b are defined herein.
L'invention concerne des composés azabicycliques 3.1.0 et 4.1.0 de formule (I), des compositions pharmaceutiques les contenant, des procédés de fabrication de ceux-ci, et des procédés d'utilisation de ceux-ci comprenant des procédés de traitement d'états pathologiques, de troubles, et de conditions associées à la modulation de MGL, telles que celles associées à la douleur, à des troubles psychiatriques, à des troubles neurologiques (notamment, entre autres, le trouble dépressif majeur, la dépression résistante aux traitements, la dépression anxieuse, le trouble bipolaire), des cancers et des affections oculaires. Dans la formule, X, Y, R1, R2a et R2b sont tels que définis dans la description.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2021160602A1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | MONOACYLGLYCEROL LIPASE MODULATORS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T08%3A22%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GARCIA-REYNAGA,%20Pablo&rft.date=2021-08-19&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2021160602A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |